Development of Standardized Fetal Progenitor Cell Therapy for Cartilage Regenerative Medicine: Industrial Transposition and Preliminary Safety in Xenogeneic Transplantation.

Details

Ressource 1Download: 2021_Biomolecules.pdf (1820.90 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_E4DA1AC43247
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Development of Standardized Fetal Progenitor Cell Therapy for Cartilage Regenerative Medicine: Industrial Transposition and Preliminary Safety in Xenogeneic Transplantation.
Journal
Biomolecules
Author(s)
Laurent A. (co-first), Abdel-Sayed P. (co-first), Ducrot A., Hirt-Burri N., Scaletta C., Jaccoud S., Nuss K., Roessingh ASB, Raffoul W., Pioletti D., Rechenberg B.V., Applegate L.A., Darwiche S.
ISSN
2218-273X (Electronic)
ISSN-L
2218-273X
Publication state
Published
Issued date
09/02/2021
Peer-reviewed
Oui
Volume
11
Number
2
Pages
250
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Diverse cell therapy approaches constitute prime developmental prospects for managing acute or degenerative cartilaginous tissue affections, synergistically complementing specific surgical solutions. Bone marrow stimulation (i.e., microfracture) remains a standard technique for cartilage repair promotion, despite incurring the adverse generation of fibrocartilagenous scar tissue, while matrix-induced autologous chondrocyte implantation (MACI) and alternative autologous cell-based approaches may partly circumvent this effect. Autologous chondrocytes remain standard cell sources, yet arrays of alternative therapeutic biologicals present great potential for regenerative medicine. Cultured human epiphyseal chondro-progenitors (hECP) were proposed as sustainable, safe, and stable candidates for chaperoning cartilage repair or regeneration. This study describes the development and industrial transposition of hECP multi-tiered cell banking following a single organ donation, as well as preliminary preclinical hECP safety. Optimized cell banking workflows were proposed, potentially generating millions of safe and sustainable therapeutic products. Furthermore, clinical hECP doses were characterized as non-toxic in a standardized chorioallantoic membrane model. Lastly, a MACI-like protocol, including hECPs, was applied in a three-month GLP pilot safety evaluation in a caprine model of full-thickness articular cartilage defect. The safety of hECP transplantation was highlighted in xenogeneic settings, along with confirmed needs for optimal cell delivery vehicles and implantation techniques favoring effective cartilage repair or regeneration.
Keywords
MACI, cartilage cell therapy, cell banking, chorioallantoic membrane model, fetal progenitor cells, large animal model, pilot safety study, preclinical research
Pubmed
Web of science
Open Access
Yes
Funding(s)
European Commission / H2020 / 833594
Create date
22/02/2021 12:38
Last modification date
19/06/2021 6:33
Usage data